Theralase Technologies Inc. TLTFF
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 118.70K | 96.70K | 162.00K | 203.00K | 158.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 118.70K | 96.70K | 162.00K | 203.00K | 158.80K |
| Cost of Revenue | 56.90K | 49.80K | 6.90K | 87.70K | 73.10K |
| Gross Profit | 61.80K | 46.90K | 155.20K | 115.30K | 85.80K |
| SG&A Expenses | 442.50K | 386.40K | 411.00K | 379.60K | 369.40K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 887.00K | 847.80K | 658.80K | 943.60K | 863.70K |
| Operating Income | -768.30K | -751.20K | -496.70K | -740.60K | -704.90K |
| Income Before Tax | -767.40K | -752.10K | -491.80K | -734.70K | -688.10K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -767.40K | -752.10K | -491.80K | -734.70K | -688.10K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -767.40K | -752.10K | -491.80K | -734.70K | -688.10K |
| EBIT | -768.30K | -751.20K | -496.70K | -740.60K | -704.90K |
| EBITDA | -748.50K | -725.10K | -461.50K | -709.60K | -677.50K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 284.02M | 265.24M | 260.67M | 250.62M | 248.54M |
| Average Diluted Shares Outstanding | 284.02M | 265.24M | 260.67M | 250.62M | 248.54M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |